Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | CETP | P11597 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31688361 | 0.83 | CYP1A2 (0.50) | PTPN1CYP1A2CYP2A6CETPFNTA | |
| SCHEMBL915284 | 0.83 | CYP1A2 (0.50) | PTPN1CYP1A2CYP2A6CETPFNTA | |
| SCHEMBL29616518 | 0.82 | PGK1 (0.50) | PTPN1CYP1A2CYP2A6 | |
| SCHEMBL915502 | 0.82 | PGK1 (0.50) | PTPN1CYP1A2CYP2A6 | |
| SCHEMBL3043405 | 0.77 | HPGD (0.52) | CETP | |
| SCHEMBL28367074 | 0.77 | TSHR (0.51) | PTPN1CYP1A2CYP2A6FNTAFNTB | |
| SCHEMBL5051290 | 0.75 | SLC1A3 (0.43) | CYP1A2CETPFNTAFNTBSLC1A3 | |
| SCHEMBL11891943 | 0.74 | CYP1A2 (0.50) | PTPN1CYP1A2CYP2A6HTR2AHTR2C | |
| SCHEMBL13486393 | 0.74 | CYP1A2 (0.55) | PTPN1CYP1A2CYP2A6RAB9AHTR2A | |
| SCHEMBL2464198 | 0.74 | PIN1 (0.49) | PTPN1CYP1A2CYP2A6FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2879675-B1 | COMPOUNDS AND METHODS FOR TARGETING HSP90 | UNIV DUKE (US) | 2019-11-13 | — | — | EP | claimed |
| US-20180186885-A1 | FZD7 SPECIFIC ANTIBODIES AND VACCINES TO TREAT CANCER AND CONTROL STEM CELL FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-07-05 | — | — | US | claimed |
| WO-2016205566-A1 | FZD7 SPECIFIC ANTIBODIES AND VACCINES TO TREAT CANCER AND CONTROL STEM CELL FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-12-22 | — | — | WO | claimed |
| WO-2016205551-A2 | FZD7 SPECIFIC ANTIBODIES AND VACCINES TO TREAT CANCER AND CONTROL STEM CELL FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-12-22 | — | — | WO | claimed |
| US-9133439-B2 | Differentiation of human embryonic stem cells | JANSSEN BIOTECH, INC. (US) | 2015-09-15 | — | — | US | claimed |
| JP-2011506455-A | — | — | 2011-03-03 | — | — | JP | claimed |
| US-20100272717-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2010-10-28 | — | — | US | claimed |
| EP-2231147-A2 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | Novartis AG (CH) | 2010-09-29 | — | — | EP | claimed |
| WO-2009076170-A2 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2009-06-18 | — | — | WO | claimed |
| US-12616733-B2 | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260041767-A1 | METHODS OF IMPROVING CELLULAR THERAPY WITH ORGANELLE COMPLEXES | UNIV HOKKAIDO NAT UNIV CORP (JP) | 2026-02-12 | — | — | US | disclosed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250290915-A1 | METHOD FOR PREDICTING RESPONSIVENESS TO THERAPY | Cancertain Limited (GB) | 2025-09-18 | — | — | US | disclosed |
| US-12359208-B2 | Thermal control of T-cell immunotherapy through molecular and physical actuation | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2025-07-15 | — | — | US | disclosed |
| WO-2007071442-A2 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007071440-A1 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007057457-A2 | NEUROENDOCRINE TUMOR TREATMENT USING MTOR INHIBITORS | NOVARTIS AG (CH) | 2007-05-24 | — | — | WO | disclosed |
| EP-1545554-A4 | METHODS AND COMPOSITIONS FOR TREATING DIABETES MELLITIS | UNIV OHIO (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1545554-A1 | METHODS AND COMPOSITIONS FOR TREATING DIABETES MELLITIS | Ohio University (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004009094-A1 | METHODS AND COMPOSITIONS FOR TREATING DIABETES MELLITIS | OHIO UNIVERSITY (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | PTPN1 1332/4885CYP1A2 1732/4885CYP2A6 697/4885 |
| US-20260041767-A1 | METHODS OF IMPROVING CELLULAR THERAPY WITH ORGANELLE COMPLEXES | TFAM, FIS1, TUFM | PTPN1 1567/4885CYP1A2 4503/4885CYP2A6 4656/4885 |
| US-20100272717-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | ANXA5, BAX, ANXA6 | PTPN1 1447/4885CYP1A2 2567/4885CYP2A6 451/4885 |
| US-12616733-B2 | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions | XBP1, MCL1, CD81 | PTPN1 1364/4885CYP1A2 4706/4885CYP2A6 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.